Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer

OBJECTIVES: Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low risk of cancer recurrence and treatment-related toxicities in early-stage node-negative, HER2-positive breast cancer. We investigated the cost-effectiveness of this regimen. METHODS: A Markov-based mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajjar, Ali, Ergun, Mehmet A., Alagoz, Oguzhan, Rampurwala, Murtuza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550431/
https://www.ncbi.nlm.nih.gov/pubmed/31166995
http://dx.doi.org/10.1371/journal.pone.0217778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550431/
https://www.ncbi.nlm.nih.gov/pubmed/31166995
http://dx.doi.org/10.1371/journal.pone.0217778

Ejemplares similares